Price movement over the last 24 hours
Abbott Laboratories vs iShares Gold Trust — how do they compare? Abbott Laboratories trades at $95.34 (market cap $166.94B), while iShares Gold Trust trades at $76.85. The key difference: Abbott Laboratories pays a 2.63% dividend while iShares Gold Trust pays none, and iShares Gold Trust is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | IAU | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $136.62 | $101.57 |
52-Week Low | $82.57 | $61.62 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
IAU trades at $78.30, up 1.02% with a bearish technical signal from moving averages while oscillators show neutrality. The stock faces resistance near $79 with support at $78. Recent news highlights strong central bank gold buying and analyst optimism for gold prices, though immediate technical indicators suggest caution.
The outlook remains mixed with bullish long-term gold fundamentals supporting IAU, but near-term technical resistance and potential Fed policy shifts pose risks. Investors should weigh strong institutional gold demand against current overbought short-term signals and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →